Welcome to our dedicated page for Lineage Cell The SEC filings (Ticker: LCTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lineage Cell Therapeutics, Inc. (LCTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biotechnology issuer. Lineage is incorporated in California and its common stock trades on the NYSE American under the symbol LCTX. Through periodic and current reports, investors can review how the company describes its allogeneic, or “off the shelf,” cell therapy programs, its proprietary pluripotent cell–based platform, and its development and manufacturing activities.
Among the most relevant documents for analysis are Lineage’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically summarize its pipeline, including OpRegen retinal pigment epithelial cell therapy for geographic atrophy secondary to age-related macular degeneration, OPC1 oligodendrocyte progenitor cell therapy for spinal cord injuries, ReSonance (ANP1) for hearing loss, PNC1 for potential treatment of vision loss, the RND1 hypoimmune induced pluripotent stem cell line, and the ILT1 islet cell transplant initiative for Type 1 Diabetes. These filings also discuss the company’s proprietary manufacturing approaches, such as its two-tiered cGMP cell banking system and AlloSCOPE framework.
Current reports on Form 8-K provide timely details on material events, including collaboration agreements, clinical and manufacturing milestones, equity financings, and governance matters. Recent 8-K filings describe, for example, a development milestone payment under the Roche and Genentech collaboration for OpRegen, a research collaboration agreement with William Demant Invest A/S for ReSonance, capital raised through a block transaction under an at-the-market offering program, and updates related to grant applications for the OPC1 program.
On Stock Titan, these filings are supplemented with AI-powered summaries designed to highlight key points from lengthy documents, helping users quickly identify disclosures related to clinical progress, collaboration economics, equity issuances, and shareholder approvals. Investors can also monitor additional SEC forms, such as proxy materials referenced in 8-K filings, to better understand Lineage’s equity incentive plans and shareholder voting outcomes.
Lineage Cell Therapeutics reported Q3 2025 results. Total revenue was $3.68 million (collaboration revenue $3.54 million). Operating loss was $3.79 million as R&D of $3.27 million and G&A of $4.19 million outpaced revenue. A large non-cash expense from the change in fair value of warrant liability ($26.56 million) drove a GAAP net loss of $29.75 million for the quarter.
Cash, cash equivalents and marketable securities totaled $40.5 million at September 30, 2025, and management states this is sufficient for at least twelve months of planned operations. Deferred revenue declined to $16.23 million as performance obligations were recognized, and warrant liabilities rose to $45.17 million. During the quarter, the company raised $1.32 million via its ATM program. The pipeline advanced: OpRegen received FDA RMAT designation in 2024 and showed positive 36‑month data in June 2025; the OPC1 DOSED study dosed its first chronic SCI participant with no significant safety events through 60 days; and a WDI collaboration will fund up to $12 million in ReSonance preclinical work. Common shares outstanding were 230,327,537 as of October 31, 2025.
Lineage Cell Therapeutics (LCTX) furnished an 8-K under Item 2.02 announcing financial results via a press release for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1. The company stated this information is being furnished, not filed, under the Exchange Act and will not be incorporated by reference except as expressly set forth by specific reference.
Jorey Chernett filed a Schedule 13G reporting beneficial ownership of Lineage Cell Therapeutics, Inc. common stock. The filer reports owning 11,445,003 shares, representing 5.01% of the class, and states sole voting and dispositive power over those shares. The filing includes an alternate line reporting 11,455,003 shares for sole voting and dispositive power, creating an inconsistency in the reported share counts. The registrant's principal office is listed in Carlsbad, California.
The filer certifies the shares were not acquired to change or influence control of the issuer and signed the filing on 09/25/2025.
Lineage Cell Therapeutics (LCTX) reported an insider notice to sell common shares under Rule 144. An earlier sale by Don M. Bailey on 09/10/2025 disposed of 80,000 shares for gross proceeds of $97,472. The current notice proposes the sale of 60,000 shares (approximate aggregate market value $96,024) to be executed on 09/24/2025 on the NYSE through Morgan Stanley Smith Barney LLC. The 60,000 shares were acquired the same day by stock option exercise and paid in cash. The filing states the seller does not possess undisclosed material adverse information about the issuer.
Lineage Cell Therapeutics (LCTX) notice records a proposed sale of 80,000 common shares under Rule 144, with an aggregate market value of $97,472. The shares are listed on the NYSE and were acquired and are proposed to be sold on 09/10/2025 following a stock option exercise paid in cash. The filing names Morgan Stanley Smith Barney LLC Executive Financial Services as the broker for the transaction and shows 228,356,290 shares outstanding, with no other sales by the filer in the past three months reported. The filer certifies no undisclosed material adverse information regarding the issuer.
Lineage Cell Therapeutics disclosed a new multi-year research collaboration with William Demant Invest 2 Aps (WDI) to advance its auditory neuronal cell transplant program, ReSonance (ANPI), aimed at treating hearing loss. WDI has agreed to fund up to $12 million in research collaboration costs over an approximate three-year term.
The collaboration focuses on completing preclinical work so the program may be ready to progress to human clinical trials under future clinical agreements to be negotiated in good faith. Each party keeps ownership of its existing intellectual property, while Project Results will generally be jointly owned, with specific provisions allowing one party to buy out the other’s interest if it decides not to continue into clinical development.
Lineage Cell Therapeutics, Inc. is registering an additional 19,500,000 common shares for issuance under its 2021 Equity Incentive Plan, following shareholder approval of a plan amendment on June 26, 2025. With this filing, the total common shares available for issuance under the 2021 Plan will not exceed 54,000,000 shares plus any Prior Plan Returning Shares that may become available over time. The plan covers stock options and restricted stock unit awards for employees, consultants, and non-employee directors, and this registration facilitates future equity-based compensation grants.
Lineage Cell Therapeutics reported stronger collaboration revenue and continued clinical progress while remaining a development-stage biotech with ongoing operating losses. Total revenues for the six months ended June 30, 2025 were $4.27 million, up from $2.85 million a year earlier, driven primarily by recognized collaboration upfront license fees. Cash and marketable securities totaled approximately $42.3 million at June 30, 2025 and management states these resources, together with available ATM capacity, are expected to fund planned operations for at least twelve months.
Operating results reflect continued R&D and G&A spending and a non-cash $14.84 million impairment of an acquired intangible asset, producing a net loss attributable to Lineage of $34.6 million for the six months. Balance sheet highlights include total assets of $90.8 million, warrant liabilities of $18.8 million (up from $6.2 million), and shareholders' equity of $47.1 million. Clinically, OpRegen showed sustained 36-month visual acuity gains in a subgroup (mean +9.0 ETDRS letters, n=5), OpRegen retains RMAT designation, and the OPC1 DOSED study has been initiated with the first chronic SCI patient treated.
On August 12, 2025, Lineage Cell Therapeutics furnished a press release announcing its financial results for the quarter ended June 30, 2025, which is provided as Exhibit 99.1. The Form 8-K states the information is being furnished, not filed, and therefore is not incorporated by reference into other filings. The filing also includes an Inline XBRL cover page as Exhibit 104. The report is signed by George A. Samuel III, General Counsel and Corporate Secretary.